Founded in 2004, CardioDx®, Inc., is a cardiovascular genomic diagnostics company located in Palo Alto, CA. As a pioneer in the field of cardiovascular genomic diagnostics, the company is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia, and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies.
At CardioDx, we fuse expertise in genomics, biostatistics, and cardiology to develop objective, reproducible tests that provide clinicians with information to enhance patient care. CardioDx was recently honored as one of FierceMedicalDevices' Fierce 15 most promising private companies. Earlier in the year, CardioDx was named the 2012 Gold Edison Award winner for science and medical. In 2010, the company was honored as a winner of the Wall Street Journal’s prestigious Technology Innovation Awards and Corus® CAD was named one of Time Magazine’s Top Ten Medical Breakthroughs.
CardioDx performs the Corus CAD test in its onsite clinical laboratory which has been certified by the Centers for Medicare and Medicaid Services (CMS) according to the Clinical Laboratory Improvements Amendments (CLIA) and is accredited by the College of American Pathologists (CAP). The CardioDx laboratory is licensed to perform tests for all 50 states.
|Agency / State||License Number|
Our guiding principles
- We are committed to improving the quality of care for patients.
- We continually seek input from healthcare providers on the development of our products and services.
- We develop our products by conducting rigorous clinical studies, employing innovative technologies, and validating results with independent patient populations.
- We deliver clinically validated and reliable products while providing unparalleled customer service.